Dr. John Halamka, Chief Information Officer for Beth Israel Deaconess Medical Center, records his experiences with infrastructure, applications, policies, management and governance.
By John D. Halamka, MD
In June, BIDMC goes live with Electronic Medication Records (EMAR) on one ward to be followed
by 3 other wards, ensuring we meet our 10% Meaningful Use Stage 2 target by the reporting period October 1-December 31, 2013.
We built a web-based, mobile friendly EMAR system that includes many visual cues and seamless integration (not interfacing) with all our existing clinical information systems.
Covidien issues revised financials, guidance detailing its operations after it spins out its pharmaceutical division in June.
Covidien (NYSE:COV) said it expects to pull the trigger on the spinout of its pharmaceuticals division near the end of June and issued guidance for its new, sleeker post-spinout profile.
Healthcare giant Becton Dickinson paid about $14 million in compliance with the medical device sales tax during the 2nd quarter, and expects to pay about $45 million in 2013.
Healthcare giant Becton Dickinson & Co. (NYSE:BDX) posted some ups and downs for its 2nd quarter of 2013, exceeding analysts' expectations on earnings but taking some hits with lowered medical device sales and a nearly 4% cut in earnings growth due to the medical device tax.
Medical device company Medtronic signed up to provide a heart rhythm monitoring and assessment component to a clinical study assessing ARCA biopharma's genetically targeted cardiovascular drug therapy.
Medical device industry heavy-weight Medtronic (NYSE:MDT) entered a collaboration agreement with ARCA biopharma, providing continuous cardiac monitoring of patients undergoing experimental treatment with a genetically targeted cardiovascular drug therapy.
An anonymous source tells Bloomberg Businessweek that Abbott pharmaceutical spin-off AbbVie will fire its cardiology drugs salesforce amid growing competition from generics.
The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.
The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.
New Jersey healthcare giant Becton Dickinson hopes to improve its pharmacy segment position with the acquisition of Cato Software Solutions and its pharmacy automation and management systems.
New Jersey healthcare giant Becton Dickinson & Co. (NYSE:BDX) acquired pharmaceutical management systems maker Cato Software Solutions in a closed-doors deal this week.